Kotsakis, Athanasios
Ardavanis, Alexandros
Koumakis, Georgios
Samantas, Epameinondas
Psyrri, Amanta
Papadimitriou, Christos http://orcid.org/0000-0001-8084-0445
Funding for this research was provided by:
AstraZeneca Greec
Article History
Received: 19 December 2017
Accepted: 10 January 2019
First Online: 18 January 2019
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki and all applicable local requirements. The original study protocol was reviewed and approved by the competent institutional review boards of the participating hospital sites before the enrollment of any patient into the study and the performance of any study-related procedure. The IRBs which approved the conduct of this study were those of the: General Hospital of Athens “Alexandra”, Athens, Greece; Prefecture General Hospital for Cancer Treatment “Agioi Anargyri”, Athens, Greece (two principal investigators); University General Hospital of Ioannina, Ioannina, Greece; General University Hospital of Heraklion, Crete, Greece; Regional Hospital for Cancer Treatment “Agios Savvas”, Athens, Greece (two principal investigators); 251 Air Force Hospital, Athens, Greece; “Mitera” Maternity Hospital, Athens, Greece; “IASO” General Hospital, Athens, Greece; General Hospital of Chania “Agios Georgios”, Crete, Greece; Piraeus Regional General Hospital for Cancer Treatment “Metaxa”, Piraeus, Greece; General Hospital of Patras “Ag. Andreas”, Patras, Greece; “Metropolitan” Hospital, Piraeus, Greece; Diagnostic Centre of Athens “Hygeia”, Athens, Greece; and “Attikon” University Hospital, Athens, Greece. All subsequent amendments of the study protocol were also approved by the competent institutional review boards. Due to the retrospective chart review design that included the collection of secondary data only and in order to minimize the risk of biasing the clinical outcomes by exclusion from study participation of deceased subjects or patients not able to provide consent, informed consent requirement was not applied.
: Not applicable.
: AK has nothing to disclose. AA has received honoraria for consultancy in advisory boards from Pfizer, Novartis and Roche. ES has received speaker honoraria from Novartis, BMS, AstraZeneca, Genesis, MSD, Amgen, Merck and Roche. GK has received honoraria for consultancy in advisory boards from Novartis, BMS, AstraZeneca, Genesis, MSD and Roche. AP has received honoraria for consultancy in advisory boards from AstraZeneca, Novartis and Roche and research grants from BMS. CP has received speaker honoraria and honoraria for consultancy in advisory boards from Novartis, AstraZeneca, Genesis, MSD, Amgen, Merck and Roche and research grants from BMS and Roche.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.